Navigation Links
Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled its first subjects in its once-daily topical diclofenac sodium patch Phase III program. The program consists of three randomized, double-blind, placebo-controlled Phase III clinical studies with Cerimon's diclofenac patch. The studies will assess the efficacy and safety of Cerimon's diclofenac patch compared to placebo for the treatment of acute pain caused by mild-to-moderate ankle sprains, wrist injuries and soft tissue injuries of the upper and lower extremities. The ankle sprain and wrist injury studies will each enroll 208 subjects, and the soft tissue injury study will enroll 400 subjects. All three studies will randomize subjects to receive Cerimon's topical diclofenac sodium patch or placebo at a ratio of 1:1.

"Results from our Phase II acute ankle sprain study have demonstrated our topical diclofenac patch can deliver effective relief of acute pain due to mild-to-moderate musculoskeletal injuries without the side effects often associated with oral NSAIDs," stated James S. Shannon, M.D., Chief Executive Officer of Cerimon Pharmaceuticals. "Based on these data, we believe our diclofenac patch will be able to address the growing physician and patient interest in prescription therapies that can deliver safe, effective and convenient site-specific pain management."

Pain Market

Musculoskeletal pain is pain that affects the muscles, ligaments and tendons. Acute musculoskeletal injuries are common and can occur during sports activities, exercise or other physical activities. Acute musculoskeletal injuries generally require rapid treatment, which often includes the administration of anti-inflammatory drugs. Optimal topical treatment should relieve acute pain and reduce swelling in the injured area to restore normal movement. In addition, it should be safe and easy to administer.

<
'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... in your ear could improve the health of your ... University of Leeds used a standard TENS machine like ... pulses to the tragus, the small raised flap at ... the ear canal. , The stimulation changed the influence ... the nervous signals that can drive failing hearts too ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research and ... Culture Supplies - Global Strategic Business Report" report to their ... Cell and Tissue Culture Supplies in US$ Thousands by the following ... separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... - For Effective ... EMBASE(R), Elsevier,s biomedical and pharmaceutical ... with QUOSA(TM) to enable,mutual customers to download and manage ... established EMBASE.com channel in QUOSA Information,Manager. , ...
... WAYNE, Pa., Nov. 28 Encorium Group, Inc.,(Nasdaq: ... organization,(CRO) conducting studies in over 30 countries for many ... that on November,21, 2008, it received a letter from ... 10-Q for the quarterly period ended September 30, 2008 ...
... SAN DIMAS, Calif., Nov. 28 Why Humans ... Bill Sardi, co-founder and formulator of Longevinex(R) (long-jev-in-ex), a nutriceutical product ... To view the Multimedia News Release, go to: , ... The film presents the " overmineralization " theory of aging ...
Cached Biology Technology:Elsevier's EMBASE.com Partners With QUOSA 2Elsevier's EMBASE.com Partners With QUOSA 3Elsevier's EMBASE.com Partners With QUOSA 4Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3Video: 8-Minute Film Documentary Explores Why Humans Age 2
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
(Date:8/20/2014)... the past few years, Virginia Tech,s Wu Feng has ... grant from the "Computing in the Cloud" program, and ... $6 million award from the Air Force on "big ... NSF and the National Institutes of Health on "big ... together the "parallel computing" aspects from each grant, he ...
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2
... EAST LANSING, Mich. -- Time marches on, ... of wildlife habitat now can monitor changes over ... and projecting future changes are essential for sustainable ... wildlife habitat," said Jianguo "Jack" Liu, Rachel Carson ...
... in The FASEB Journal ( http://www.faseb.org ) suggests that pregnant ... babies who are likely to become junk food junkies themselves. ... the high fat and high sugar diet leads to changes ... only does this offer insight into the ever-increasing rate of ...
... 23, 2011 -- Structural studies of some of ... way for new generations of biologically inspired solar ... St. Louis and the Department of Energy,s Oak ... analyze the structure of chlorosomes in green photosynthetic ...
Cached Biology News:'Junk food' moms have 'junk food' babies 2Neutron analysis yields insight into bacteria for solar energy 2
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... familiar interface for data capture, recording, ... transition from paper to this powerful ... contains an integrated LIMS, notary service, ... These functions allow LABTrack to achieve ...
High voltage electrophoresis power supply...
Biology Products: